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PROBLEM

CONCLUSIONS

• Limited ongoing data regarding medications
related to Osteonecrosis of the Jaw

BACKGROUND
• Osteonecrosis of the jaw (ONJ) is defined as the
presence of exposed bone in the mouth, which fails
to heal after appropriate intervention over a period
of 6-8 weeks
• ONJ is a rare but serious adverse drug reaction
(ADR) commonly associated with bisphosphonate
and denosumab therapy
• FAERS is a large database of voluntarily reported
adverse drug reactions associated with post-marked
FDA-approved medications as well as natural
substances, vaccines, and medical devices
• Prior research utilized the FAERS Database to
explore this ADR.
• Previously identified drug classes associated with
ONJ included bisphosphonates, RANKL inhibitors,
antiangiogenic agents, and m-TOR inhibitors
• Proposed mechanism of action (MOA):
antiresorptive properties and bone
remodeling impairment via alterations
in the formation of new blood vessels

OBJECTIVE
• Our study aims to build upon the prior findings,
reporting trends of medication induced ONJ over
time and identifying newly described medications

METHODS
• By May 2021, the FAERS database contained a total
of 22,002,078 reported cases of ADRs
• We searched the FAERS database for all reported
cases of medication related osteonecrosis of the
jaw (MRONJ) from 2010-2021
• Cases lacking patient age or gender were
excluded. Only adults (18+) and reports from
Healthcare Professionals were included. Duplicate
cases were removed
• The top 20 medications were identified and
described for April 2010-December 2014 (“Time
Period 1”) and April 2015-January 2021 (“Time
Period 2”)

RESULTS
• Between 2010-2014: 64.7% female, 35.3% male;
average age was 66.1 +/- 11.1 years
• Between 2015-2021, 64.3% female, 35.7% male;
average age was 69.2 +/- 11.5 years
• Novel drugs and classes described between 20102014:
• Lenalidomide,
• Corticosteroids (prednisolone and
dexamethasone)
• Docetaxel and paclitaxel
• Letrozole
• Methotrexate,
• Imatinib
• Teriparatide
• Novel drugs and classes described between 20152021:
• Palbociclib,
• Pomalidomide
• Radium-223
• Nivolumab
• Cabozantinib
• Zoledronic acid was the most frequently reported
medication associated with ONJ during Time
Period 1
• Denosumab was the most frequently reported
medication associated with ONJ during Time
Period 2

Top 10 Drugs: 2010-2014
1.Zoledronic Acid: 1903 cases; 60.8%
2.Alendronate: 576 cases: 18.4%
3.Denosumab: 506 cases; 16.2%
4.Pamidronate: 301 cases; 9.6%
5.Ibandronate: 112 cases; 3.6%
6.Lenalidomide: 82 cases; 2.6%
7.Risedronate: 81 cases; 2.6%
8.Sunitinib: 56 cases; 1.8%
9.Bevacizumab: 50 cases; 1.6%
10.Prednisolone: 42 cases; 1.3%

Top 10 Drugs 2015-2021
1.Denosumab: 3148 cases; 54.5%
2.Zoledronic Acid: 2027 cases: 35.1%
3.Alendroante: 447 cases; 7.7%
4.Ibandronate: 200 cases; 3.5%
5.Lenalidomide: 150 cases: 2.6%
6.Pamidronate: 115 cases; 2.0%
7.Bevacizumab: 114 cases; 2.0%
8.Prednisolone: 103 cases; 1.8%
9.Risedronate: 101 cases; 1.7%
10.Dexamethasone: 99 cases; 1.6%

• While stricter inclusion criteria and removal of
duplicate cases led to fewer overall identified
cases of MRONJ when compared to prior research,
our data represents a more reliable analysis of
MRONJ reports to the FAERS database with
improved accuracy
• Our study identifies cases of several newly
described drugs and drug classes that have not
been previously described in literature and
provides further description of the various
medications associated with ONJ and elucidate
patient demographics associated with the ADR
• Further evaluation of the MOA of these
medications, including anti-angiogenesis,
immunomodulation, cytotoxicity, and hormonal
effects may shed light on their potential to
contribute to this ADR
• A limitation of this study includes the use or
exposure to multiple medications, making it
difficult to determine the individual causes of
MRONJ as well as the clinical indication for these
drugs
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